SARS disease information you've heard NO WHERE yet:
1. HTLV (Human T-cell Leukemia Virus) infection will likely interfere with established SARS partial immunity and likely allow for the reactivation of SARS disease in healthy carriers.
2. SARS coronavirus may be passaged from mother to child either in utero or during neonatal life.
3. Children infected by their mothers with SARS coronavirus will probably not usually develop SARS but become immune carriers of the virus for a period of 5-6 months.
4. Recovery from the SARS coronavirus carrier state is likely associated with a loss of premunition immunity.
5. SARS coronavirus likely targets CD13 (aminopeptidase N) on cell-surfaces and will cause increase in interferon-alpha, interleukin-6, soluable CD23, and tumor necrosis factor-alpha. CD64- people may be more seriously affected. CD14 and CD16 may also be of interest relative to SARS disease processes.
6. SARS coronavirus may target glial (nerve) cells and sequelae of the disease may include multiple sclerosis and schizophrenia as the SARS coronavirus may activate HERV-W retrotransposons in some individuals. Additionally, there is a likelihood that SARS may later increase likelihood for development of lymphocytic leukemia in some persons.
7. SARS disease infectivity appears, though caused by a coronavirus, to be somewhat related to Newcastle Disease Virus, a paramyxovirus of birds and to Avian infectious bronchitis virus, a coronavirus of birds. Study of transmission vectors of NDV and AIBV may offer insight into SARS disease transmission in humans.
8. Individuals may carry SARS coronavirus in their system for as long as 6 months after recovery; they can be infective to others during this time.
9. Some individuals are silent carriers of the SARS coronavirus. Class II Major Histocompatibility Complex Human Leukocyte Antigen genetics appear to determine who is a carrier and who gets the disease and how serious the disease symptoms are. Some people may be entirely and completely resistant to infection by the SARS virus, i.e., likely to be approximately 1% to 10% of Northern European populations.
10. SARS coronavirus mortality rate may exceed 18% in HLA-DR, -DP, -DQ predominate countries.
11. Immunosuppressed individuals will not likely get the serious hyperimmune illness of SARS but they may develop a persistent infection with SARS coronavirus and be infective to others. This has implications for HIV+ individuals and disease control/quarantine policies.